Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development expenses	$ 1,883	$ 21,287	$ 7,761	$ 40,793
General and administrative expenses	2,600	4,086	8,533	17,693
Total operating expenses	4,483	25,373	16,294	58,486
Other (income) expenses:
Other (income) expense, net	(464)	83	(785)	105
Loss before income tax benefit	(4,019)	(25,456)	(15,509)	(58,591)
Income tax benefit	0	0	(4)	(28)
Net loss	$ (4,019)	$ (25,456)	$ (15,505)	$ (58,563)
Net loss per share of common stock — basic (in dollars per share)	$ (0.05)	$ (0.35)	$ (0.21)	$ (0.80)
Net loss per share of common stock — diluted (in dollars per share)	$ (0.05)	$ (0.35)	$ (0.21)	$ (0.80)
Weighted-average shares of common stock outstanding — basic (in shares)	73,975,196	73,335,279	73,905,737	73,046,889
Weighted-average shares of common stock outstanding — diluted (in shares)	73,975,196	73,335,279	73,905,737	73,046,889